Parkinsons L-dopa questions raise hope and caution
Dr Thosteson answers readers about the new drug L-dopa for Parkinsons disease. He notes limited availability and high cost, varying patient responses from modest to dramatic, possible side effects, and the need for physician access to experimental units. He also discusses magnets in toys and safety.